Literature DB >> 15634003

Nucleotides and pronucleotides of 2,2-bis(hydroxymethyl)methylenecyclopropane analogues of purine nucleosides: synthesis and antiviral activity.

Zhaohua Yan1, Earl R Kern, Elizabeth Gullen, Yung-Chi Cheng, John C Drach, Jiri Zemlicka.   

Abstract

Phenylmethylphosphor-L-alaninate pronucleotides 7a, 7b, 8a, and 8b, cyclic phosphates 10a and 10b, and phosphates 11a and 11b derived from 2,2-bis(hydroxymethyl)methylenecyclopropane analogues 1a, 1b, 2a, and 2b were synthesized and evaluated for their antiviral activity. An improved protocol for the synthesis of analogues 1a, 1b, 2a, and 2b is also described. Phosphate 11a was the most effective agent against human and murine cytomegalovirus (EC(50) 0.25-1.1 microM). The Z-pronucleotides 7a and 7b had EC(50) 3.6-25.2 and 3-18.4 microM, respectively. The EC(50) of cyclic phosphate 10a was 6.0-20 microM. The activity against Epstein-Barr (EBV) was assay-dependent. Pronucleotides 7a and 7b and phosphate 11a had EC(50) 2.3-3.4 microM against EBV/H-1, but 7b was cytotoxic (CC(50) 3.8 microM). Cyclic phosphate 10a was the only compound effective against EBV/Daudi (EC(50) 0.96 microM), but it was inactive in H-1 cells. Pronucleotide 7a was active against varicella zoster virus with EC(50) 6.3 and 7.3 microM, respectively, and hepatitis B virus (HBV, EC(50) 4.1 microM). Cyclic phosphate 10a was the most effective analogue against HBV (EC(50) 0.8 microM).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15634003     DOI: 10.1021/jm040149b

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  Synthesis and enantioselectivity of cyclopropavir phosphates for cellular GMP kinase.

Authors:  Chengwei Li; Brian G Gentry; John C Drach; Jiri Zemlicka
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2009-09       Impact factor: 1.381

2.  9-{[3-fluoro-2-(hydroxymethyl)cyclopropylidene]methyl}adenines and -guanines. Synthesis and antiviral activity of all stereoisomers1.

Authors:  Shaoman Zhou; Earl R Kern; Elizabeth Gullen; Yung-Chi Cheng; John C Drach; Sadahiro Tamiya; Hiroaki Mitsuya; Jiri Zemlicka
Journal:  J Med Chem       Date:  2006-10-05       Impact factor: 7.446

3.  Potency and Stereoselectivity of Cyclopropavir Triphosphate Action on Human Cytomegalovirus DNA Polymerase.

Authors:  Han Chen; Chengwei Li; Jiri Zemlicka; Brian G Gentry; Terry L Bowlin; Donald M Coen
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

4.  New access to H-phosphonates via metal-catalyzed phosphorus-oxygen bond formation.

Authors:  Laëtitia Coudray; Isabelle Abrunhosa-Thomas; Jean-Luc Montchamp
Journal:  Tetrahedron Lett       Date:  2007-09-10       Impact factor: 2.415

5.  Synthesis and antiviral activities of methylenecyclopropane analogs with 6-alkoxy and 6-alkylthio substitutions that exhibit broad-spectrum antiviral activity against human herpesviruses.

Authors:  Mark N Prichard; John D Williams; Gloria Komazin-Meredith; Atiyya R Khan; Nathan B Price; Geraldine M Jefferson; Emma A Harden; Caroll B Hartline; Norton P Peet; Terry L Bowlin
Journal:  Antimicrob Agents Chemother       Date:  2013-05-13       Impact factor: 5.191

6.  L-valine ester of cyclopropavir: a new antiviral prodrug.

Authors:  Zhimeng Wu; John C Drach; Mark N Prichard; Milka Yanachkova; Ivan Yanachkov; Terry L Bowlin; Jiri Zemlicka
Journal:  Antivir Chem Chemother       Date:  2009-09-25

7.  Phosphonate analogues of cyclopropavir phosphates and their E-isomers. Synthesis and antiviral activity.

Authors:  Santosh B Mhaske; Bashar Ksebati; Mark N Prichard; John C Drach; Jiri Zemlicka
Journal:  Bioorg Med Chem       Date:  2009-04-17       Impact factor: 3.641

8.  Fluorinated methylenecyclopropane analogues of nucleosides. Synthesis and antiviral activity of (Z)- and (E)-9-{[(2-fluoromethyl-2-hydroxymethyl)-cyclopropylidene]methyl}adenine and -guanine.

Authors:  Chengwei Li; Mark N Prichard; Brent E Korba; John C Drach; Jiri Zemlicka
Journal:  Bioorg Med Chem       Date:  2007-12-05       Impact factor: 3.641

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.